Search filters

List of works by Chantal Doyen

A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation

scientific article published on 28 April 2016

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

scientific article published on 23 November 2010

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

scientific article published on 13 October 2009

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

scientific article published on 17 August 2011

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study.

scientific article published on 18 March 2017

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

scientific article

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial

scientific article published on 19 June 2019

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

scientific article

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

article

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

scientific article published on 27 July 2006

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

scientific article published on 01 August 2019

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

scientific article

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

scientific article

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

scientific article published on 20 June 2016

Paulina is supported by:

About Paulina

Help